What development phase is IVABRADINE HYDROCHLORIDE in?

IVABRADINE HYDROCHLORIDE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IVABRADINE HYDROCHLORIDE

FDA-approved approved Small molecule Quality 0/100

Ivabradine hydrochloride is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	IVABRADINE HYDROCHLORIDE
Modality	Small molecule
Phase	FDA-approved
First approval	2005

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IVABRADINE HYDROCHLORIDE CI brief — competitive landscape report
IVABRADINE HYDROCHLORIDE updates RSS · CI watch RSS